Our team leads the NHLBI-funded PROACT trials, aimed at testing the impact of a proactive, polygenic-risk based detection strategy on cardiovascular health and coronary atherosclerosis. The PROACT trials leverage the power of polygenic risk scores in identifying people at high risk of heart attack currently “flying under the radar” and advances in noninvasive coronary plaque imaging. The innovative design uses a genomic-based enrichment strategy for a clinical trial to test single or dual targeting of lipid-lowering and inflammation in coronary atherosclerosis.

PROACT 1: Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health NCT05819814 The purpose of PROACT 1 is to assess the impact of disclosing a high polygenic risk score result for coronary artery disease on change in cardiovascular health.

PROACT 2: Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine NCT05850091 The purpose of PROACT 2 is to determine how treatment with high intensity statin, low-dose colchicine, or their combination modulates progression and composition of coronary atherosclerosis in individuals with high polygenic risk for coronary artery disease.